Dave Yamauchi

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

Auayporn Nademanee, Stephen J. Forman, Arturo Molina et al. · Blood · 2005 · 200 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Phase II Trial of a Transplantation Regimen of Yttrium-90 Ibritumomab Tiuxetan and High-Dose Chemotherapy in Patients With Non-Hodgkin's Lymphoma

Amrita Krishnan, Auayporn Nademanee, Henry C. Fung et al. · Journal of Clinical Oncology · 2007 · 158 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.

Jeffrey Y.C. Wong, Stephen Shibata, Lawrence E. Williams et al. · PubMed · 2003 · 97 citations

Medicine, Oncology, Radiation Oncology +17

Pilot Trial Evaluating an 123I-Labeled 80-Kilodalton Engineered Anticarcinoembryonic Antigen Antibody Fragment (cT84.66 Minibody) in Patients with Colorectal Cancer

Jeffrey Y.C. Wong, David Z. J. Chu, Lawrence E. Williams et al. · Clinical Cancer Research · 2004 · 90 citations

Medicine, Oncology, Pharmacology +17

A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.

Wong JYC, David Z. J. Chu, Dave Yamauchi et al. · PubMed · 2000 · 87 citations

Medicine, Oncology, Pharmacokinetics +11